Diagnos (FRA:4D4A) Cyclically Adjusted PB Ratio: (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4D4A Diagnos Inc FRA:4D4A
34 GF Score
Price €0.29
GF Value €0.08
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Diagnos Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diagnos  (FRA:4D4A) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Diagnos Cyclically Adjusted PB Ratio Related Terms


Diagnos Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Diagnos's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnos Cyclically Adjusted PB Ratio Chart

Diagnos Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Diagnos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:4D4A vs VEEV, BTSG, TEM: Cyclically Adjusted PB Ratio Comparison

For the Health Information Services subindustry, Diagnos's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diagnos Cyclically Adjusted PB Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Diagnos's Cyclically Adjusted PB Ratio falls into.


FRA:4D4A
34GF Score
Diagnos Inc FRA:4D4A
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnos Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Diagnos's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Diagnos's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.004/132.2623*132.2623
=0.004

Current CPI (Mar. 2026) = 132.2623.

Diagnos Quarterly Data

Book Value per Share CPI Adj_Book
201606 -0.231 102.002 -0.300
201609 -0.179 101.765 -0.233
201612 -0.137 101.449 -0.179
201703 -0.136 102.634 -0.175
201706 -0.060 103.029 -0.077
201709 -0.093 103.345 -0.119
201712 -0.091 103.345 -0.116
201803 -0.132 105.004 -0.166
201806 -0.173 105.557 -0.217
201809 -0.200 105.636 -0.250
201812 -0.134 105.399 -0.168
201903 -0.158 106.979 -0.195
201906 0.000 107.690 0.000
201909 0.001 107.611 0.001
201912 -0.006 107.769 -0.007
202003 0.019 107.927 0.023
202006 0.014 108.401 0.017
202009 0.010 108.164 0.012
202012 0.011 108.559 0.013
202103 0.011 110.298 0.013
202106 0.010 111.720 0.012
202109 0.007 112.905 0.008
202112 0.002 113.774 0.002
202203 -0.001 117.646 -0.001
202206 -0.008 120.806 -0.009
202209 -0.013 120.648 -0.014
202212 -0.015 120.964 -0.016
202303 -0.019 122.702 -0.020
202306 -0.022 124.203 -0.023
202309 -0.026 125.230 -0.027
202312 -0.026 125.072 -0.027
202403 -0.027 126.258 -0.028
202406 -0.020 127.522 -0.021
202409 -0.007 127.285 -0.007
202412 -0.003 127.364 -0.003
202503 0.001 129.181 0.001
202506 -0.005 129.892 -0.005
202509 -0.009 130.287 -0.009
202512 0.008 130.366 0.008
202603 0.004 132.262 0.004

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Diagnos (FRA:4D4A) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnos stock appears to be overvalued. The current stock price of €0.29 is trading 267.5% above its estimated GF Value™ of €0.08. GuruFocus considers Diagnos to be Significantly Overvalued.

Key valuation signals for FRA:4D4A:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €0.08 vs. price of €0.29 (267.5% above fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the FRA:4D4A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diagnos Business Description

Other Exchanges DGNOF:USAADK:Canada
Address 7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
34GF Score

Get the complete analysis for FRA:4D4A

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.29
Price
€0.08
GF Value